InspireMD Inc (NSPR) Q4 2025 Earnings Call Transcript

Why It Matters

The coding shift could sharply cut physician reimbursement, threatening procedure adoption and pressuring Inspire’s revenue trajectory, while the company’s operational progress and cash position provide a buffer against these headwinds.

Key Takeaways

• Q4 revenue up 12% to $269M; FY2025 $912M.
• 2026 revenue guidance $950‑$1,000M, 4‑10% growth range.
• CPT 64582 with -52 modifier may cut fees 10‑50%.
• Inspire 5 training complete; >90% centers ready.
• WISER prior‑auth program causing Medicare delays.

Pulse Analysis

Inspire Medical Systems’ latest earnings underscore a robust market position in the implantable hypoglossal nerve stimulator space. The 12% fourth‑quarter revenue lift and 14% full‑year growth were powered by a mix of sales leverage and an expanding center footprint, delivering an operating margin that improved on both a quarterly and annual basis. Strong cash generation—$52 million in Q4 operating cash flow and a $405 million cash balance—allowed the company to repurchase $50 million of stock in the quarter, signaling confidence in its balance sheet while returning value to shareholders. These financial fundamentals set a solid platform as the firm navigates a competitive sleep‑apnea therapy market.

However, the most consequential variable for 2026 is the pending CPT coding transition for the Inspire 5 system. The shift to code 64582 with a -52 modifier could erode professional fees by anywhere from 10% to 50%, depending on Medicare Administrative Contractor (MAC) policies. Such a fee reduction threatens physician willingness to adopt the newer device, potentially curbing procedure volumes and compressing net income. Management is pursuing short‑term mitigation—advocacy with payers and leveraging the higher surgical complexity of Inspire 5—to limit fee cuts, while also exploring a dedicated CPT code in the long run. This reimbursement uncertainty injects a wide range into the company’s revenue guidance, reflecting the material risk to its growth outlook.

On the product front, Inspire 5 rollout appears on schedule, with physician training finalized and more than 90% of contracted centers equipped to implant the device. Complementary digital tools like SleepSync, now FDA‑cleared for 3‑Tesla MRI compatibility and enhanced with a prior‑authorization feature, aim to streamline patient access and reduce administrative friction. Territory management is being optimized toward a 1:1 manager‑representative ratio, bolstering field coverage. Looking ahead, the upcoming Inspire 6 platform promises auto‑activation capabilities, positioning the company for next‑generation sleep‑apnea therapy. Investors should weigh the upside of continued product adoption against the downside of coding‑driven reimbursement risk when assessing Inspire’s valuation.